Our site uses cookies so you have a better experience of the site and so that you can place orders. Find out how to manage your cookies.

GM Journal

Price: £147.00
Editor(s): Alison Bloomer
GM Journal is the leading monthly publication focusing on healthcare of the 50 plus patient, helping you to meet the challenges of age-related diseases. 

GM Journal is written for doctors by doctors, bringing all of the latest news and reviews to physicians in primary and secondary care.

In each issue of GM you will find practical clinical articles which exemplify best practice in all the therapeutic areas relevant to the care of older people, written by leaders in their respective fields. All of our articles undergo a stringent peer-review process and are overseen by an editorial board of leading physicians in our specialist areas.

Formerly titled Geriatric Medicine, GM is the leading journal with a focus on older people's healthcare and plays a pivotal role in helping its readers to meet the challenge of managing age-related diseases. A one year subscription gets you twelve print issues of the journal, delivered monthly straight to your door.

GM also organises a well-established annual conference, speakers are key physicians with particular interests in diseases of midlife and beyond. Aimed at both primary and secondary care physicians, previous event topics have included diabetes, COPD prevention strategies, pain management, urinary incontinence, skin problems, end of life care, Parkinson’s disease, hypertension and secondary prevention of stroke.

Managing Editor Alison Bloomer can also be found on Twitter – follow @gmandgm2journal to keep up to date on current website articles, conference news, and all of Alison’s latest blogs.

Doctors and GPs with an interest in the health of older people, commissioners, CCGs, medical professors, geriatricians, psychologists, psychiatrists, senior nurses and other hospital doctors.
ISSN: 0268-201X
Content: GM Journal brings you all the very latest information on clinical advances, new guidelines, licensed treatments, political developments, non-drug interventions and developmental therapies.